Picture of Imugene logo

IMU — Imugene Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Momentum

Relative Strength (%)
1m-23.88%
3m-16.96%
6m+2.35%
1yr+187.9%
Volume Change (%)
10d/3m-22.25%
Price vs... (%)
52w High-44%
50d MA-27.61%
200d MA-7.46%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-27.58%
Return on Equity-29.57%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for IMU

Imugene hits 52w high – but will it continue? background image

Imugene hits 52w high – but will it continue?

It's a good time to be a shareholder in Imugene (ASX:IMU): as the share approaches its 52-week high, holders may be wondering whether to sell and take the profit, or buy more and ride the uptrend. Shares in Imugene are currently tradin...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202230th Jun 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Imugene EPS forecast chart

Profile Summary

Imugene Limited is an Australia-based clinical-stage immuno-oncology company. The Company is engaged in developing immunotherapies that seeks to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness the body’s immune system against cancerous tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with care drugs and immunotherapies such as chimeric antigen receptor T cells (CAR T’s) for solid tumors. Its PD-1 B-cell immunotherapy, known as PD1-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies for the treatment of cancers. Its clinical trial candidates include VAXinia (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.

Directors

Last Annual
June 30th, 2021
Last Interim
June 30th, 2021
Incorporated
May 30th, 1986
Public Since
December 2nd, 1993
No. of Shareholders
20,001
No. of Employees
0
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
au flag iconAustralian Stock Exchange - SEATS
Shares in Issue
4,962,841,567

IMU Share Price Performance

FAQ

Or unlock with your email

Or unlock with your email